Sernova Corp. (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) today announces a regulatory collaboration with CTI Clinical Trial and Consulting Services on Sernova’s Cell Pouch System.
According to the press release:

CTI as an expert in cell therapy, and immunology among other life-changing therapies in critically and chronically ill patients is supporting Sernova’s clinical trial regulatory processes including submission of Sernova’s regulatory package with the FDA for the recently announced JDRF supported clinical trial in patients with insulin-dependent diabetes.

Sernova’s CEO, Dr. Philip Toleikis, said the following:

“We at Sernova see this collaboration as the beginning of a long-term relationship in supporting the clinical development progression of our therapeutic cell and device applications. With their clinical trial experience across six continents in bringing research sites, patients, and sponsors together, CTI will be an invaluable member of Sernova’s development team.”

 Read the full press release here.